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Cancer is simply defined as an "abnormal growth of the 
cells". Temin (1970) has defined cancer as "a disease in 
which cells are genetically altered in such a way, that in 
normal environment, the altered cell respond to the normal 
control of cells multiplication with more multiplication 
than the normal cells." 
All of the various cell types of the body can give rise 
to cancer cells. Cancer cells are usually cloiser in their 
properties to immature normal cells than to more mature cell 
types. They respond abnormally to the control mechanisms 
that regulate the division of normal cell, and they continue 
to divide in a relatively uncontrolled fashion until they 
kill the host (Pierce et al. , 1978; Cairus, 1978, Medrano & 
Pardee, 1980). Cancer can be thought of as a "wound that 
does not heal" (Beauchamp et aj.. , 1989). Susceptibility to 
cancer is a polygenic phenomenon. The influence of non-
genetic factors, such as hormones, nutritional status or 
chronic inflammation may modulate the development of 
neoplasia in a manner parallel to the phases of initiation 
and promotion seen in chemical carcinogenesis (Miller, 
1980) . 
The involvement of personality factor or stress m the 
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evolution of human cancer dates back to 175 AD when Galen 
stated that 'melancholy' women were more prone to cancer 
than their 'sanguine' counterparts. Moore (1979) proposed 
that sociological stress in women may be one of the factor 
in the etiology of breast cancer. The relationship betwcni 
stress, hormones and various neurotransmitter is now we]1 
established. Due to stress the circulating level of 
catecholamines, have been found considerably enhanced (Click 
et al. , 1965; Berson and Yellow, 1968; Kvetnausky, 1972; 
Mikulaj, 1975; Pandey, 1976; Rai, 1977 and Kopui et aj . , 
1980). Exact cause of malignant disease is not yet known. 
Various theories have been provided uptil now; stress is one 
of the possible factor responsible for oncogenesis (Riley, 
1975; Seiffer, 1976; Baldwin, 1979; Moore, 1979 and Udupa et 
al., 1980). 
Furth (1975) hypothesized that hormones are not direct 
carcinogen but are indispensable component in 
carcinogenesis. Chronic irritation of the oesophageal mucosa 
is considered as one of the predisposing factor leading to 
carcinoma of oesophagus, alongwith smoking and alcohol 
consumption (Wynder and Bross, 1961; Gray et al., 1992; 
Palli et al., 1992). 
The effect of habitual smoking and drinking on the 
subsite of gastric cancer has not been determined so far, 
there being differing results concerning the association of 
these habits (MacDonald and MacDonald, 1987; Wu-Williams et 
al., 1990; Gray et al., 1992; Palli et al., 1992). In 
stomach 90-95% tumors turn out to be malignant (Cox, 1969). 
Serum Lactate dehydrogenase has been found enhanced in all 
the cases of cancer. Two to three fold increase of LDH is 
associated with fall of plasma cholinesterase level. This 
relationship is most marked in Lymphomas (Ghooi et aj . , 
1980). 
Similar to LDH the activities of certain enzymes are 
elevated in the gastric juice of patients with Gastrjc 
Carcinoma (Symrniotis et al., 1962). Serum Histaminase level 
are found significantly enhanced in the patients of 
medullary carcinoma of thyroid (Baylin et aj.. , 1970). The 
level of histaminase in the malignant effusion fluid are 
used as tumor markers (Chiwei, 1979). 
Fresh vegetables are known to be protective factor 
against gastric cancer as well as cancer of other sites 
(Risch et al., 1985; Trichopoules et aJ., 1985; Correa et 
al., 1985; Chyou et aJ., 1990; Hirayama, 1990). Several 
other substances such as Vitamin A, C, E and dietary fibre 
contained in vegetables and fruit also demonstrated anti-
carcinogenic effect (Greenwald et aj., 1986). Lower 
concentration of tissue c-Amp have also been reported in 
adenocarcinoma of Colon (DeRobertris et a_l . , 1976) and 
cancer breast (Patel et aj.. , 1981), alongwith enhanced 
catecholamine level (Udupa et al., 1980; Patel et aJ . , 
1981). Decreased activities of Monoamineoxidase, cytocliorme 
oxidase, succinic dehydrogenase are found in both benign and 
malignant neoplasia and also in hyperplastic lesions 
(Wattenberg, 1959 and McGuity et al., 1971). Generally the 
activity of some enzymes which are not essential for the 
process of rapid growth of the tissue are decreased in such 
situation. 
In the present study the circulating levels of AchP], 
Histaminase and MAO were estimated in various cancer 
patients before and after therapy. These levels were 
compared with the normal controls of comparable age and sex. 
RiVISW 
ilUHATURS 
Cancer is a most dreadful disease. It represents a 
fundamental aberration in cellular behavior that involves 
many aspects of molecular biology. 
Susceptibility to cancer is a polygenic phenomena. In 
addition, the influence of non-genetic factors sucli as 
hormones, nutritional status or chronic inf laimiicit j on nn\ 
modulate the development of neoplasia ]n a manner parallel 
to the phases of initiation and promotion seen m chemrcal 
carcinogenesis (Miller, 1980). It is now generally 
recognized that most oxogenous carcinogens require metabolic 
transformation into an active form and that the abaJity to 
activate these substances varies widely from individual to 
individual (Miller, 1978). Similar genetic control may be 
operating with regards to endogenous carcinogens as well 
(Lewan & Reilly, 1974). A precise parallel exist between the 
metabolism of oxogenous carcinogens and the metabolism of 
pharmacologic agents. A limited immune deficiently may also 
play a role in the etiology of primary hepatocellular 
carcinoma (Larouze ejt al. , 1977), 
Furth (1975) hypothesized that hormones are not direct 
carcinogen but are indispensable component m 
carcinogenesis. The hormones enhance cell division and thus, 
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favour the somatic mutation or unmasking mutations brought 
about earlier m response to carcinogens, in effect acting 
as promoters. The studies m mice showing the enhancing 
effect of hormones on breast cancer induction, supports this 
view (Bittner, 1957). Dyer et al. (1975) have shown that 
hypersensitive patients carry higher risk of cancer 
development under certain circumstances. 
Cancer can arise as the result of exposure to a variety 
of agents, studies have revealed that pure chemicals 
themselves are able to produce cancer (MiJler, 1978). It is 
generally accepted that a high proportion of human rancet is 
attributed to environmental agents, mainly rheniicaJ. Tho 
distribution of carcinogens in the environment is 
essentially ubiquitous. The human diet contains a variety of 
naturally occuring mutagens and carcinogens (Ames, 1981). 
The N-nitroso compound form a large group of agents, occur 
widely in the environment (Bartsch and Montesano, 1984). 
Many of them are carcinogens m experimental animaJs 
(Bogovoski and Bogovski, 1982; Magee et al., 1982) and are 
causative agents m some human cancer (Bartsch and 
Montesano, 1984). Major percentage of N-nitroso compounds 
are alkylating agent which react with nucleic acids and 
other cellular molecules and exert many of their hiuJoqirdl 
effect as a result of the transfer of an alkyl group 
(Miller, 1978; Magee et al., 1982; O'Connor et al . , 1979). 
Majority of chemical carcinogen are known to form covalent 
adducts with DNA, thus indicating DNA as a critical target 
in chemically induced cancer (Miller, 1978; O'Connor, 1981). 
Colon and digestive tracts are exposed to variety of 
carcinogens derived from the rancidity of fats (Simic and 
Karel, 1980; Bisckoff, 1969; Petrakis et al., 1980; Imai et 
al., 1980; Ferrali et aj., 1980). 
Hydrogen peroxide, generated by the oxidation of 
dietary fatty acid by peroxisomes, is a known mutagen and 
carcinogen (Reddy et al., 1982; Plain, 1955). Some Hydrogen 
peroxide may escape in the peroxisomes and contribute to the 
supply of oxygen radicals (Speit et aj., 1982; Jones et aj . , 
1980), which in turn can damage DNA and can start the 
rancidity chain reaction, which lead to the production of 
the mutagens and carcinogens (Pryor, 1976-1982). 
One of the theories of etiology of cancer which is 
being widely accepted, holds that the major cause is damage 
to DNA by oxygen radical and lipid peroxidation (Ames, 1983; 
Totter, 1980). Certain promotors of carcinogenesis acts by 
generation of oxygen radical. Fats and H2O2 are among the 
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most potent promoters (Welsch and Aylsworth, 1983). Other 
well known cancer promoter are lead, calcium, phorbolesters, 
asbestors and various quinones. Many carcinogens which do 
not require the action of promoters and are by themselves 
able to induce carcinogenesis (complete carcinogens), also 
produce oxygen radicals (Demopoules et aj.. , 1980). These 
include nitroso compounds, hydrazines, quinones and 
polycyclic hydrocarbons. Much of the toxic effect of 
ionizing radiation damage to DNA is also due to the 
formation of oxygen radical (Totter, 1980). 
Recent advances in molecular biology have led to the 
concept that carcinomas arise from the accumulation of a 
series of genetic alterations involving activation of proto-
oncogenes and inactivation of tumor suppressor genes. p53 is 
a tumor suppressor gene located on chromosome 17p 13 and 
mutation at this locus are the genetic abnormalities most 
frequently found in a variety of human malignancies, 
including gynecologic cancer (Fearon et al., 1987; Okamato 
et al., 1991; Marks et al., 1991; Milner et a]., 1993; Nigra 
et al., 1989; Takahashi et al., 1989). 
Coffee contains a mutagenic pyrolysis procJtirt 
methylglyoxal (Sugimura and Sato, 1983). There is 
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inconclusive evidence to suggest that heavy coffee drinking 
is associated with cancer of the ovary, pancreas, bladder 
and the large bowel (Trichopoulos et al . , 1980). 
Sodium bisulphite anion used as food 
additive/preservative reacts specifically with uracil and 
cytosine within single stranded region of DNA and RNA. It is 
also mutagenic to bacteria and bacteriophages (Singer, 
1983) . 
Chronic irritation of the oesophagus mucosa is 
considered as one of the predisposing factors leading to 
carcinoma of oesophagus, alongwith smoking and alcohol 
consumption (Wynder & Bross, 1961). In stomach 90% to 95% 
tumors turn out to be malignant (Cox, 1969). 
The isolation stress is known to increase the activity 
of enzyme responsible for metabolic activation of 
carcinogens, without influencing their excretion, and may 
therefore adversely affect carcinogenesis (Capel and 
Williams, 1979). Lower concentrations of tissue C-AMP have 
been reported in adenocarcinoma of colon (De Roberts et al . , 
1976) and cancer breast (Patel et al., 1981), alongwith 
enhanced catecholamine level (Udupa et aj., 198U; Patel et 
al., 1981). 
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Serum Lactate dehydrogenase level has been found 
enhanced in all the cases of cancer. Two to three fold 
increase of LDH is associated with fall of plasma 
cholinesterase level. This relationship is moat marknd in 
lymphomas. Further fall of plasma cholinesterase level is 
found to indicate that the disease is fairly advanced and 
had probably spread to the liver (Ghooi et al • , 1980). 
Similar to LDH the activation of certain enzymes are 
elevated in the gastric juice of patients with Gastric 
carcinoma (Symrniotis et al., 1962). Serum Histaminase level 
are found significantly enhanced in the patients of 
medullary carcinoma of thyroid (Baylin et aj., 1970). The 
level did not fall even after removal of tumor with 
metastases (Baylin et al., 1972). The level of plasma 
histaminase have also been reported to be increased in 
carcinoma (Casti et aJ.. , 1963 and Majumdar et aJ. . , 1969) and 
endometrical carcinoma (Borglin and Wiliest, 1962). Th(? 
level of histaminase in the malignant effusion fluid are 
used as tumor markers (Chiwei, 1979). Decreased activities 
of monoamine oxidase, cytochrome oxidase. Succinic 
dehydrogenase are found in both benign and malignant: 
neoplasma and also in hyperplastic lesions (Wattenberg, 1959 
and Mc Guity et al., 1973). Generally the activity of some 
12 
enzymes which are not essential for the process of rapid 
growth of the tissue are decreased in such situation. 
Involvement of stress in the evolution of human cancer 
dates back to 175 AD when Galen stated that 'melancholy' 
women were more prone to cancer than their 'sanguine' 
counterparts. Other workers also reported that grief and 
mental depression is associated with breast cancer (Cutter, 
1887) . 
Moore (1979) proposed that sociological stress in women 
may be one of the factor in the etiology of breast cancer. 
Several other convincing evidences are there to incorporate 
the involvement of stress in the development of tumors 
(Seiffer, 1976 and Udupa et al., 1980). 
The stomach occupies a position of priority in human 
pathology because of its continous exposure to chemicals, 
physical and psychological stress, which is considered as 
one of the predisposing factors in the development of the 
numerous disorder common to the organ. The cancer of the 
stomach constitutes approximately 40% of all cancers in the 
Gastrointestinal tract. Many workers have correlated the 
psychological factors with human cancer (Cobb, 1952; Cutler, 
1954 and Corson, 1966). 
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Malignant neoplasia undoubtedly elicit the typical 
manifestation of the General Adaptation Syndrome (G.A.S.) 
both in animals and in man (McEven and Selyc, 1935; Moore et 
ad., 1969 and Ertl, 1973). They produce hypertrophy and 
hyperactivity in the adrenal cortex, an increase in plasma 
and urinary corticoids and their metabulil.es, involuLion of 
the thymolymphatic apparatus etc. (Ertl, 1973). Many type of 
cancer develope at sites of local chronic stress (Selye, 
1979) . 
The relationship between stress hormones and various 
neurotransmitter is now well established. During stress the 
increase in the activity of sympatho-hypothalamo-pituitary-
adrenal system has been observed (Kvetnansky and Mikulaj, 
1970). In response to stress, the hyperactive pituitary 
gland releases the tropic hormones which in turn by acting 
on their target endocrine gland stimulate the synthesis and 
release of their respective hormone (Levi, 1967). Thus, due 
to stress the circulating level of catecholamines, Cortisol, 
ACTH, growth hormones, acetylcholine, histamine have been 
found considerably enhanced (Click et al., 1965; Berson and 
Yelow, 1968; Kvetnansky, 1972; Mikulaj et a 1., 1975; Pandey, 
1976; Rai, 1977 and Kopui et al., 1980). 
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An increased acetylcholine level is observed after 
stress (Aprison and Huigton, 1969). Also an increased levels 
of both Ach and AchE are reported after electric shock 
(Singh et al., 1980). 
It has been reported that cigarette smoking and aldohol 
promote the development of Gastric cancer especially in 
Cardia. An unequivocal effect of habitual smoking and 
drinking on the subsite of gastric cancer has not been 
determined so far, there being differing results concerning 
the association of these habits (MacDonald and MacDonald, 
1987; Wu-Williams et al. , 1990; Gray et aj . , 1992; PaUi et 
al. , 1992). Several studies have reported tliat the risk of 
lung cancer decreased after quitting smoking (Hirayama, 
1990; Sobue et al., 1991). However, the effect of stopping 
smoking may be less expected in gastric cancer than in lung 
cancer. In gastric cancer, it is suggested that past rather 
than current smoking is the risk factor. Smoking is also 
reported to be the major risk factor for the oesophageal 
cancer (Hirayama, 1990). The relative risk of ex rather than 
current drinking was higher in Gastric cancer. Several 
carcinogenic substances have been extracted from tobacco 
smoke (Hoffman et al . , 1991) but those present in alcolio] 
have yet not been identified. In a view of tliis, it is 
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suggested that cigarette smoking may play main role m 
initiation and alcohol may promote the development of 
gastric cancer especially in Cardia (Mac Donald & Mac 
Donald, 1987; Wu-Williams et al., 1990; Gray et al., 1992; 
Palli et al., 1992). 
Investigation of the role of diet in the etiology of 
breast cancer have been focussed principally on fat and 
energy (Rohan and Bain, 1987). It has been found that 
vegeterian women have different hormone profiles and lower 
incidence of breast cancer as compared to their omnivorous 
counterparts (Hill et al . , 1980; Armstrong e_t a^l • , 1981; 
Goldin §t al., 1982; Shultz, 1986). The mechanism by which 
dietary fibre/associated plant compounds may influence 
estrogen metabolism is being investigated (Rose, 1990). It 
appears that fibre rich food may either interfere with tlie 
enterohepatic cycling of estrogen (Goldin et ad., 1982; 
Shultz and Howie, 1985) or reduce its bioactivity 
(Adlercrutz et al., 1986). These mechanism suggests 
relatively high fibre intake might be associated with 
reduced risk of breast cancer, hypothesis which has received 
support in some (Lubin et al. , 1986; Van't Veer et aj. . , 
1990; Lee et al., 1991; Rohan et al., 1993) but not ail 
(Kushi et al., 1992; Willett et al., 1992) epidemiological 
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1982). Also oxygen radicals arise from phagocytosis after 
viral and bacterial injection (Tauber, 1982). The enzymes 
that protect cells from oxidative damage are superoxide 
dismutase, glutathione peroxidase (Pryor 1976-1982), D.T 
diaphorase (Lind et al., 1981) and glutathione transferases 
(Warholm et al., 1981). In addition, some small molecules m 
the human diet act as antioxidant agent sucli as Tocopherol 
(Vit-E) in membranes (Pryor 1976-1982) decrease the carcrino-
genic effect of quinones, adriamycin and daunomycin which 
are toxic because of free radical generation (Ames, 1983). 
Tocopherols also protect against radiations and 
dimethylhydrazine induced carcinogenesis (Beckman, ej; § J • , 
1982). Thus, fresh vegetables are known to be protcct;i\e 
factor against gastric cancer as well as cancer of other 
sites (Risch et al. , 1985; Trichopoulos et a^l . , 1985; Correa 
et al., 1985; Chyou et al., 1990; Hirayama, 1990). Several 
other substances, e.g. Vitamin A, C, E and dietary fibip 
contained in vegetables and fruit also demonstrat(?tl 
anticarcinogenic effect (Greenwald et al., 1986). B-carotene 
is another potent antioxidant present in the dint, .jiul \'3 
important in protecting lipid membranes against oxidation. 
Carotenoids have been shown to be anticarcinogenic in fats 
and mice and may also have a similar effect m liunian 
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(Mathews-Roth, 1982; Peto et al., 1980). Dietary glutathione 
is also an effective anticarcinogen against aflatoxins 
(Novi, 1981). Selenum is another important dietary 
anticarcinogen present in the active site of glutathione 
peroxidase, which is essential for destroying lipid 
hydroperoxides and endogenous hydrogen peroxides and 
therefore help to prevent oxygen radical induced lipid 
peroxidation (Flohe, 1982). Uric acid present in high 
concentration in the blood of humans is also a strong 
antioxidants (Ames et al., 1981). In addition, edible plants 
contain variety of substance such as phenols that have been 
reported to inhibit or enhance carcinogenesis and 
mutagenesis in experimental animals (Ames, 1983). 
Acetylcholinesterase (AchE) 
Acetylcholinesterase is an enzyme whose physiological 
function is hydrolysis of the neurotransmitter acetylcholine 
(Quinn, 1987; Rosenberry, 1975; Taylor, et al., 1971). It 
was discovered by David Nachmansohn in 1938. The name 
acetylcholinesterase was proposed by Augustinsson and 
Nachmansohn (1949). One molecule of enzyme may split one 
molecule of Acetylcholine in about 3 to 4 microseconds. 
Extensive studies on the concentration and distribution of 
AchE in conductive tissue have shown that significant amount 
FIGURE I : Metabolism of Acetylcholine 
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0 
CH3—N —CH2CH2 - O - C —CH3 
Acetylcholine 
acetylthiokinase 
HS-CoA + ATP + acetate > Acetyl CoA + H2O + ADP 
choline acetylase 
Acetyl CoA + Choline > Acetyfchofine + HS-CoA 
cholinesterase 
Acetylcholine + H2O > Choline + acetate 
Fig. ( I ) 
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of Ach may be split per gm of tissues within milliseconds, 
i.e. within a period of time during which the impulse passes 
(Nachomansohn, 1939). The concentration of the enzyme is 
high in all nerve tissues. Nerve fibres are capable of 
hydrolyzing amount of Ach ranging usually from 5 to 50 mg 
per gm fresh tissues per hour. Alles & Hawes (1940) showed 
that erythrocyte esterase differ markedly from serum 
esterases. Richter and Croft (1942) confirmed that Red Cell 
esterase is highly specific for Ach. Zeller and Bissenger 
(1943) found that brain esterase is fundamentally similar to 
red cell esterase. The rate of hydrolysis of Ach was found 
-3 
to be optimal at about 6 to 8x10 M substrate 
concentration. Higher concentration increasingly inhibit the 
rate of hydrolysis. The function of Acetylcholine in RBC is 
unknown but Braner & Root (1945) found the enzyme is located 
in the surface of Red Cells. The membrane environment of red 
cell is also important for the enzyme reactivity (Flis, 
1979). 
Monoamine Oxidase (MAO) 
Monoamineoxidase was first reported in Liver by Hare 
(1928). Blaschko et al. (1937) have shown that adrenaline 
noradrenaline and other catechol compounds can act as 
substrates for MAO. It exist m mammalian tissues m a 
FIGDRE II : Metabolism of Histamine 
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Fig. ( ii) 
22 
multiple form. MAO of rat brain is classified into two forms 
A & B according to its sensibility towards clergyline 
(Johuston, 1961). The form which LS sensitive to clergyline 
IS called type A while the more resistant to clergyline is 
type B. Neff et al., (1973) have show that serotonin and 
noradrenaline are specific substrate for type A while 
benzylamines and phenylethylammes are specific for type B 
enzyme. Dopamine, tyramme and tryptamine are common 
substrate for both the enzymes. However, both forms of the 
enzymes are not found m all the tissues (Fuller & Roush, 
1972). The deamination mechanism for both types are the same 
MAO 
RCH2NH2 + O2 + H2O > RCHO + NH3 + H2O2 
One mole of O2 is required for the oxidation of one 
mole of substrate. MAO acts only on those amine which have 
an amino group attached to the terminal Carbon atom 
(Blaschko, 1952). When the amino group is directly attached 
* 
to the benzene ring, deamination does not occur, but 
phenylethylammes and benzylamine are metabolized. If the 
amino group is not attached to the terminal Carbon atom of 
the amines as m amphetamine and adrenaline, they are not 
metabolized by MAO. MAO is known as the principal enzyme 
taking part m the deamination reaction (Yasunobu e_t al . , 
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1968). Generally all the vertebrates contain MAO. The usual 
source of MAO are the mitochondria of liver, brain (Weiner, 
1960), adrenal gland, kidney and pheripheral and central 
nervous system (Blaschko et al., 1955). It is also found m 
heart, salivary gland, spleen and nonadrenergic granules 
(Tripton et al., 1976). 
Inhibitors of MAO play a significant role in the 
metabolism of catecholamine, serotonin and other amines 
(Zellet et al•r 1952). The first monoamine oxidase inhibitor 
i.e. Hydrazine was found in 1952. The use of such inhibitor 
increases the concentration of neurohumors and decreases the 
excretory metabolite like VMA & HVA. However, the 
concentration of normetanephrine, metanephrine and 
octopamine are increased following administration of MAO 
inhibitors (Sjaerdsma, 1966). The evidence that tlie two 
forms of MAO results from differences m membrane lipid 
binding suggest that the activity of the enzyme m vivo 
might be affected by drugs and diseases that affect lipid 
metabolism. 
Histaminase 
A slow disappearance of histamine was observed by Dale 
and Laidlaw (1912) in liver perfusion experiments. In 1915 
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Eutis reported the inactivation of histamine by the ground 
liver of the turky buzzard. The inactivation of histamine by 
various animal tissues has been shown (Best, 1929 Sc Mcllcnry 
& Gavin, 1932) to involve an oxidative deamination. 
Originally, Best & McHenry (1930) introduced the term 
histaminase, an enzyme now known to be associated with the 
deamination of Histamine. 
The general reaction for the enzyme catalyzing the 
oxidative deamination of Histamine is as follows 
Histaminase 
R.CH2NH2 + O2 + H2O > RCHO + NH3 -t HoOo 
Certain studies have revealed that histaminase activity 
is a property of two mammalian enzymes which are closely 
related chemically, but differ in their substrate 
specificity (Buffoni, 1966). Both the enzymes are present in 
human; one in the tissues and placenta (Kapeller-Adler,196 5 ) 
and the other in the blood plasma (McEwen and Cohen, 1963). 
^It has been shown that histaminase is a flavoprotein 
(Kapellar-Alder, 1949). It was also suggested that 
histaminase and related oxidases are pyridoxal enzymes 
(Werle & Pechamaun, 1949 & Davidson, 1956). Vitamin Bg and 
B2 work as the cofactor for histaminase (Goryachenkova, 1956 
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and Kapellar Adler & MacFarlance, J9G3). Manduvic GL al . , 
(1963) reported that purified pig kidney histaminase is not 
a flavaprotein but contains copper. Zeller (1963) emphasized 
that the enzyme contains two negatively charged binding 
sites. 
The increase m enzyme activity is dependent on its 
release by the tissues. In the guinea pigs the liver is the 
most important source of enzyme and its release may be 
mediated through the concomitant release of heparin (Giertz 
et al., 1964 and Schmutzler et al., 1965). Giertz (1964) has 
shown in experimental observation on perfused guinea pigs 
liver that heparin has m fact the ability to release liver 
histaminase. 
The level of histaminase is generally high m the 
intestinal mucosa (Waston, 1956) and it is absent in brain 
(Janson & White, 1964). The toxicity of Histamine is lower 
when given orally as compared to parentally administered 
(Bovet & Bovent Nilti, 1948). The metabolic pathway 
catalyzed by histaminase has the role of limiting the 
biological effects of oxogenous histamine or of the 
endogenous histamine escaping in the circulation when it is 
released in large amount. 
MAmiAL 
MiWOOS 
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NORMAL 
Control : 
Twenty healthy and normal volunteers (7 males and 13 
females, age ranging between 22-60 years) were selected and 
they served as normal controls. 4-5 ml heparinized blood was 
collected from each volunteers. The plasma was separated by 
centrifugation and utilized for the estimation of 
Histammase (Arsen and Kemp, 1964), Monoamine Oxidase 
(McEven and Cohen, 1971) and the erythrocytes were used for 
the estimation of Acetylcholinesterase (Ellman et aj.. , 1961). 
CLINICAL (Gastrointestinal Tract Malignancy) 
Cancer Oesophagus, stomach and colon 
This study included total 30 patients suffering from 
cancer oesophagus (8), cancer stomach (10) and cancer colon 
(12). These cases were admitted in the surgical ward of J.N. 
Medical College, Aligarh, Muslim University. Detailed 
clinical history of each case was recorded and diagnosis was 
confirmed by surgery and histopathological examinations. 
Blood from each patient was collected and was subjected for 
the estimation of AchE, Histammase and MAO. 
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Cancer Gall Bladder 
Eight patients suffering from cancer gall bladder were 
included in this series. Blood was collected both before and 
'after treatment (Chemotherapy, radiotherapy and surgrry) and 
was subjected for the assay of AchE, Histaminase & Monoamine 
Oxidase. 
Cancer Liver 
10 cases of cancer liver were included. The diagnosis 
was confirmed by surgery and histopathological examinations. 
Blood from each patient was collected at the time of 
admission and after 10 days of chemotherapy and surgery 
which was subjected for the assay of above mentioned 
biochemical parameters. 
Cancer Breast 
This study included 12 patients. Blood was collected 
both before and after 10 days of surgical therapy. The 
detailed clinical history of each patient was recorded and 
the diagnosis was confirmed by surgery and Histopathological 
examinations. Blood was subjected for the estimation of 
AChE, MAO and Histaminase. 
Acetylcholinesterase (ElIman et al., 1961) 
Principle : The enzyme catalyses the hydrolysis of 
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substrate acetylthiocholine iodide into thiocholine and 
acetate. The thiocholine thus formed reacts with 
dithiobisnitrobenzoate to give yellow colour. The 
absorbance of this yellow color is measured in the 
spectrophotometer. 
AchE 
Acetylthiocholin > Thiocholine + Acetate iodide 
Thiocholine + dithiobisnitrobenzoic acid > Yellow colour 
(absorbed at 412 nm) 
Reaction : 
AChE 
(CH3)3NCH2CH2SCOCH3 > (CH3)3N^ -- CH2 -- CIH -- S 
Acetyl thiocholine Thiocholine 
+ 
CH3C00~ + 2H 
acetate 
(CH3)3N — CH2 — CH2 — s' + R - S.S.R. 
thiocholine DTNB 
— -> (CH3)3NCH2CH2SSR + RS 
Where R O2N 
'5 - thio - 2 - nitrobenzoic acid (II) 
Reagents : 
1) Phosphate buffer pH 8.0, O.lM, Phosphate buffer pH 7,0, 
O.IM, AR (BDH). 
2) Substrate; Acetylthiocholine iodide 0.075 M (21.67 mg/ 
ml) (Stable for 10-15 days if kept rcf rigcra) otj 
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(Sigma Chemical Co., USA). 
3) Sodium bicarbonate AR (BDH). 
4) Reagent: Dithiobis, nitrobenzoic acid (DTNB) (Sigma 
Chemical Company, USA). O.OlM of the 5,5'dithiobis-2-
nitrobenzoic acid 39.6 mg were dissolved in 10 ml of pU 
7.0 phosphate buffer (O.lM) and 15 mg of sodium 
bicarbonate were added. The reagent was made up in 
buffer of pH 7.0 in which it was more stable than in 
that of pH 8.0. 
5) Working blood solution: 10 yl (0.01 ml) of washed 
erythrocytes were suspended in 6.0 ml of 0.1 M 
phosphate buffer of pH 8.0 (dilution, 1:600). Since 
the AchE is bound on the cell membrane of RBC, 
hemolysis was not necessary. 
Method for RBC : Exactly 3.0 ml of the suspension of washed 
RBC (dilution, 1:600) were pipetted into a cuvette, 25 vl of 
DTNB reagent were added. The cuvette was then placed into 
the spectrophotometer and its slit was adjusted so that. the 
absorbance (at 412 nm) of the suspension m the cuvette was 
zero. 20 yl of the substrate were added to this cuvette 
changes in absorbance at 412 nm were recorded for at least 6 
30 
minutes. Protein was estimated in the rest 3 ml suspension 
of RBC by the method of Lowry et aj . (1951). 
Calculations : Moles substrate hydrolyzed/min/mg protein 
600 A 
= 0.0441 X 
(4.41).10 ^ 
13,600 Protein 
A 
Protein 
-5 
Where 4.41(10 ) = factor for dilution and extinction 
coefficient 
Quantitative Estimation of Proteins : 
The procedure described by Lowry et aj.. , (1951) was 
followed. A suitable eliquot of the protein sample (washed 
erythrocytes) was diluted to 1.0 ml with distilled water. To 
this was added 5.0 ml of freshly prepared Copper reagent. 
The copper reagent was prepared by mixing 0.5% Copper 
sulphate 1% (W/V), sodium potassium tartarate 2% (W/V), 
sodium carbonate in O.lN NaOH in 1:50 ratio. After 
incubation for 10 minutes at room temperature, 0.5 ml of 1 N 
Folin's reagent was added. The contents were rapidly mixed 
and colour intensity was read after 30 minutes against a 
reagent blank at 660 nm. The concentration of proteins in 
the samples were determined using a standard curve with F^ SA. 
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Plasma Histaminase (Arsen and Kemp, 1964) : 
Principle : Histaminase acts on Histamine forming the 
product imidazole acetaldehyde, hydrogen peroxide and 
ammonia. During incubation period, the colourless 
orthodiansidine dye gets converted to a coloured compound 
whose optical density is measured in spectrophotomter. The 
increase in optical density during incubation is the measure 
of the Histaminase activity and the activity is expressed in 
provisional unit. 
Provisional Onits : 
One provisional unit is defined equal to that which may 
produce an increase of 0.01 in Optical density at 470 nm 
after incubation for 4 hours at 37°C. 
Reagents : 
1) 0.1 M sodium phosphate buffer pH 7.2. 
2) 0.2 M histamine diphosphate solution in distilled water 
3) 4 mg/100 ml peroxidase (Horse-radish) type T in 
distilled water. 
4) 1 mg/ml of Ortho-diansidine solution in 96% alcohol. 
5) Freshly centrifuged clear plasma. 
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Procedure : For each samples two tubes were used and 
incubation mixture was prepared as follows 
Control Tube Experimental Tube 
Buffer 3.0 ml Buffer 3.0 ml 
Buffer 0.15 ml Histami ne 
diphosphate 
0.15 ml 
Peroxidase 0.15 ml Peroxidase 0.15 ml 
0-Diansidine 0.15 ml O-Dianisidme 0.15 ml 
Plasma 0.20 ml Plasma 0.20 ml 
Both the tubes were incubated at 37°C in colourless 
condition. At the end of 4th hour, the optical density of 
the coloured solution of both the tubes were measured and 
the activity of the Histaminase was calculated with 
difference of the readings of Control and Experimental tubes 
measured at 470 nm in Beckman U.V. spectrophotometer. 
Plasma Monoamine Oxidase (MAO) (McEven & Cohen, 1963 
modified by McEven, 1971 
Principle : The measurement of MAO activity depends on the 
conversion of amine to aldehyde. The substrate benzylamine 
is converted into benyaldehyde which is extracted in the 
Organic layer (cyclohexane) and is measured spectroplioto-
metrically at 242 nm 
RCH2NH2 -> RCHO + NH 
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Reagents : 
1) Phosphate buffer 0.2 M, pH 7.2 (BDH) 
2) Benzylamine 8 nM in 0.2 M Phosphate buffer pH 7.2 (Ward 
Blenkinsop & Co. Ltd., London) 
3) Perchloric acid 60% (E. Merck) 
4) Cyclohexane AR (BDH) 
Method : To 1 ml of plasma, 1.25 ml of phosphate buffer 
and 0.25 ml of substrate (benzylamine) was added. This was 
incubated in Dubnoff's metabolic shaker for 3 hours. The 
reaction was stopped by the addition of 0.25 ml of PCA. A 
control tube was also run alongwith it, in which substrate 
was added after stopping the reaction. The mixture in both 
Control & Experimental tube was shaken thoroughly and 2.5 ml 
of cyclohexane was added. The aldehyde was extracted by 
shaking thoroughly in 2.5 ml of cyclohexane. It was stirred 
and allowed to stand for 15 minutes at room temperature. The 
emulsion was " centrifuged and the cyclohexane layer was 
separated. This step was repeated with 2.5 ml of 
cyclohexane. The absorbance of the cyclohexane extracts were 
measured at 242 nm in silica cells against plane 
cyclohexane. 
Content of the tubes 
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Control Tube Experimental Tube 
Plasma 1.0 ml Plasma 1 .0 ml 
Buffer 1.25 ml Buffer 1.25 ml 
PCA 0.25 ml Benzylamine 0.25 ml 
Benzylamine 0.25 ml PCA 0.25 ml 
Calculations : The difference of 0.01 in Optical density in 
between Control and Experimental sample using 1 ml plasma is 
equivalent to one provisional unit (P.U.). The result were 
expressed in terms of P.U. (Provision Unit)/ml of plasma. 
a 
DISCUSSION 
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Levels of Neurohumors and their enzyme in Normal Subjects 
In the present study, the circulating AchE, Histaminase 
and MAO were estimated in normal human volunteers of both 
the sexes. The circulating level of AchE, and MAO were 
slightly raised in females then in males, though the 
difference were not statistically significant. The activity 
of plasma Histaminase was found significantly higher in 
females as observed by Rai (1977) also. 
Raised circulating levels of catecholamines have in 
males (Frankenhaeuser et al., 1976). The slight difference 
observed in the neurohumoral levels and the activities of 
their enzymes in females may be due to difference in 
hormones. 
Cancer of Oesophagus, Stomach and Colon 
The circulating level of RBC AchE, Plasma Histaminase 
and Plasma MAO were significantly altered in cancer patients 
in comparison to the control (p < 0.001) (Table 1, 2 & 3; 
Fig. Ill, IV & V). 
The level of RBC AchE and plasma Monoamine oxidase is 
found significantly (p < 0.001) lower in patients of cancer 
oesophagus, stomach and colon (Table 1, 2 & 3; Fig. Ill, IV, 
& V). The activity of Histaminase is significantly increased 
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Table-1 : Changes in the circulating level of Acetylcholine-
sterase, Histaminase and Monoamine oxidase in 
cancer oesophagus before and after treatment 
(Mean+S.E.M.) 
Normals 
(15) 
Cancer 
Oesophagus 
(8) 
After 
treatment 
(4) 
RBC AchE 
-5 (ymoles/min/mgxlO ) 
Plasma Histaminase 
(P.U/ml) 
5.541 
±0.148 
30.587 
±1.069 
3.587 
±0.128 
82.861' 
±4.216 
4.815 
±0.079 
56.113 
±2.725 
b 
Plasma Monoamine 
Oxidase (P.U/ml) 
11.034 
±0.214 
7.827 
±0.122 
9.260 
±0.109 
The numbers in Paranthesis indicate the number of patients. 
Abbreviations 'a' and 'b' indicate level of significance 
a b 
p < 0.001, p < 0.01 in comparison to normal. 
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Table-2: Effect of treatment on the circulating level of 
AchE, Histaminase and Monoamine oxidase in cancer 
stomach before and after tratment 
Normals 
(15) 
Cancer 
Stomach 
(10) 
After 
treatment 
(8) 
RBC AchE 
-5 
Plasma Histaminase 
(P.U/ml) 
5.541 
(vmoles/min/mgxlO ) ±0.148 
30.587 
±1.069 
1.746 
±0.039 
85.911' 
±1.637 
3.513 
±0.150 
38.515 
±1.557 
b 
Plasma Monoamine 
Oxidase (P.U/ml) 
11.034 
±0.214 
4.818 
±0.177 
6.959 
±0.183 
The numbers in Paranthesis indicate the number of patients. 
Abbreviations 'a' and 'b' indicate level of significance 
p < 0.001, p < 0.01 in comparison to normal. 
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Table-3: Alterations in the circulating AchE, Histaminase 
and Monoamine oxidase in cancer colon before and 
after treatment (MeantS.E.M.) 
RBC AchE 
— 5 (ymoles/min/mgxlO ) 
Plasma Histaminase 
(P.U/ml) 
Plasma Monoamine 
Oxidase (P.U/ml) 
Normals 
(15) 
5.541 
±0.148 
30.587 
±1.069 
11.034 
±0.214 
Cancer 
Coloy 
(12) 
3.410^ 
±0.025 
88.534^ 
±3.216 
8.696^ 
±0.182 
After 
treatment 
(6) 
4.010^ 
±0.024 
56.326^ 
±3.818 
9.570^ ^ 
±0.356 
The numbers in Paranthesis indicate the number of patients. 
Abbreviations 'a' and 'b' indicate level of significance 
p < 0.001, p < 0.01 in comparison to normal. 
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(p < 0.001) in all the cancer patients conipnrcd to 1 IHM r 
normal control (Fig. Ill, IV & V). 
Even after surgery and chemotheraphy the level of all 
these biochemical parameter remained significantly altered 
in comparison to control values, although a tendency of 
reversion to control values is observed. 
Cancer Gall-Bladder 
The circulating level of Histaminase is significantly 
raised (p < 0.001) as compared to controls in cancer gall-
bladder patients (Table 4). The activities of plasma MAO is 
also significantly enhanced while RBC AchE activity is 
significantly lowered (p < 0.001) as compared to controls 
(Fig. VI). The al'tered levels remained elevated aft or 
treatment (Table 4; Fig. VI). 
Cancer Liver 
In the patients of cancer Liver the circulating level 
of Histaminase is significantly raised (p < 0.001) as 
compared to control whereas the activities of I^ BC AcliL' and 
plasma MAO is significantly lowered (p < 0.001) (Table 5; 
Fig. VII). After treatment (Surgery, chemotherapy and 
radiotherapy) all these parameters remained significantly 
altered, although the levels reverted slightly towards 
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Table-4: Changes in circulating Acetylcholinesterase, 
Histaminase and Monoamine oxidase level in cancer 
gall-bladder before and after surgery (Mean + S. E'.M. ) 
Cancer After 
Normals Gall-bladder treatment 
(15) (8) (4) 
RBC AchE 
-5 
5.541 
(Mmoles/min/mgxlO ) iO.148 
3.136 
±0.026 
4.102 
±0 .032 
Plasma Histaminase 
(P.U/ml) 
30.587 
il.069 
68.665 
±3.087 
47.616 
±0.98 9 
Plasma Monoamine 
Oxidase (P.U/ml) 
11.034 
±0.214 
15.637 
±0.393 
b 
12.2 5 0 
±0.152 
The numbers in Paranthesis indicate the number of pationts. 
Abbreviations 'a' and 'b' indicate level of siqnificance 
a b 
p < 0.001, p < 0.01 in comparison to normal. 
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Table-5 : Changes in circulating level of Acetylcholineste-
rase, Histaminase and Monoamine oxidase in 
patients of cancer liver before and after 
treatment (Mean±S.E.M.) 
Normals 
(15) 
Cancer 
Live 5^  
(10) 
After 
treatment 
(6) 
RBC AchE 
-5 
5.541 
(ymoles/min/mgxlO ) ±0.148 
3.900 
i0.054 
4.359 
±0.075 
Plasma Histaminase 
(P.U/ml) 
30.587 
±1.069 
89.851 
±1.848 
a 59.661 
±1.552 
Plasma Monoamine 
Oxidase (P.U/ml) 
11.034 
±0.214 
4.014 
±0.295 
a 5.66 3 
±0.172 
The numbers in Paranthesis indicate the number of patients 
Abbreviations 'a' and 'b' indicate level of significance 
a 
p < 0.001 in comparison to normal. 
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control values. 
Cancer Breast 
Circulating Histaminase level is increased while RBC 
AchE and plasma MAO activities were decreased in the 
patients of Breast Cancer. After surgery these levels 
reverted towards control values except the level of plasma 
Histaminase and Monoamine oxidase (Fig. VIII) which remained 
elevated even after therapy. 
All the parameters changed gradually from 1st stage 
(refer to primary tumor of less than 2 cm in diameter and 
uninvolved axillary lymph nodes) to 3rd stage (characterize 
by primary tumor greater than 5 cm in diameter) in th(^  
patients of breast cancer. Minimum changes were observed at 
1st stages and maximum at 3rd stage (Table 7; Fig. TX) of 
cancer development. 
Cancer Stomach with Secondary in Liver 
Plasma Histaminase level is significantly enhanced (p < 
0.001), while erythrocyte AchE and plasma MAO activities 
were decreased significantly (p < 0.001) in these patients 
(Table 8; Fig. X). After 30 days of treatment (surgery, 
radiotherapy and chemotherapy), these levels were foui\d 
significantly (p < 0.001) altered when compared to the 
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Table-6 : Effect of surgery on circulating AcotyJoholinos-
terase, Histaminase and Monoamine oxidase level in 
cancer breast patients (MeaniS.E.M.) 
Normals 
(15) 
Cancer 
Breas]^ 
(12) 
After 
treatment 
(6) 
RBC AchE 
-5 (ymoles/min/mgxlO ) 
5.541 
±0.148 
3.034 
±0.028 
4.211 
±0.062 
Plasma Histaminase 
(P.U/ml) 
30.587 
±1.069 
77.736 
±1.840 
5 0.76 2 
±1.564 
Plasma Monoamine 
Oxidase (P.U/ml) 
11.034 
±0.214 
5.527 
±0.210 
8.277 
±0.192 
The numbers in Paranthesis indicate the number of patients. 
Abbreviations 'a' and 'b' indicate level of significance 
a 
p < 0.001 in comparison to normal. 
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Table-7: Changes in the circulating levels of Acetylcholine-
sterase, Histaminase and Monoamine oxidase in cancer 
breast at different stages. 
Normals I II III 
(15) 
RBC AchE _ 5.541 4.332^ 3.242^ 3.000^ 
(ymoles/min/mgxlO ) ±0.148 i0.126 ±0.129 ±0.025 
Plasma Histaminase 30.587 41.460^ 62.600^ 72.536^ 
(P.U/ml) ±1.069 ±1.318 ±1.727 ±0.838 
Plasma Monoamine 11.034 8.971^ 6.831^ 6.223^ 
Oxidase (P.U/ml) ±0.214 ±0.189 ±0.164 ±0.117 
* 
The numbers in Paranthesis indicate the number of patients. 
Abbreviations 'a' and 'b' indicate level of significance 
a 
p < 0.001 in comparison to normal. 
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Table-8: Changes in the circulating levels of Acetylcholine-
sterase, Histaminase and Monoamine oxidase in cancer 
stomach with secondary in liver before and after 
treatment 
Normals 
(15) 
Before 
treatment 
(8) 
After 
treatment 
(6) 
RBC AchE 
-5 
5.541 
(ymoles/min/mgxlO ) ±0.148 
3.027 
±0.102 
2.783 
±0.184 
Plasma Histaminase 
(P.U/ml) 
30.587 
±1.069 
162,297 
±10.350 
121.199 
±2.697 
Plasma Monoamine 
Oxidase (P.U/ml) 
11.034 
±0.214 
4.307 
±0.354 
4.547 
±0.208 
The numbers in Paranthesis indicate the number of patients. 
Abbreviations 'a' and 'b' indicate level of significance 
a 
p < 0.001 in comparison to normal. 
FIGURE IX : Changes in the circulating levels of Acetyl-
cholinesterase, Histaminase and Monoamine 
oxidase in cancer breast at different stages. 
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level in cancer breast patients. 
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primary cancer patients. 
The trend of changes observed in the levels of 
neurohumors is nearly the same in all cancer patients 
independent of site of cancer. Thus, in all the cancer 
patients the circulating level of Histaminase is found 
significantly enhanced were as the activities of RBC AchE 
and plasma MAO were decreased significantly in the cancer 
patients of oesophagus, stomach, colon, liver, breast and 
metastatic cancer patients. The activity of MAO, the 
metabolizing enzymes of catecholamines, showed a different 
trend in the cancer of gall-bladder. The patients of cnicer 
gall bladder showed a significant rise in the leveJ (if MAO. 
All these alterations were found more pronounced jn the 
cancer patients having metastases. After one month of 
chemotherapy, radiotherapy and surgery all the above 
biochemical parameter remained significantly altorr-d t.hnn 
the controls, in all the cancers except cancer brea^ i^t. A 
positive correlation is observed between the rise and fall 
of these parameters and stages of breast cancer. 
The exact cause of malignant disease is not yet Icnown. 
Various theories have been propounded upti J now; sti'pss is 
also included as one of the possible factors responsible for 
55 
oncogenesis (Riley, 1975; Seifler, 1976; Baldwin, J 979; 
Moore, 1979 and Udupa et al., 1980). Stress is known to 
alter the activity of AchE, its degrading enzyme (Litvak, 
1969). Thus, the decreased level of AchE as observed in the 
cancer patient may be due to the stress of the disease 
itself. Cancer being such a dreadful disease, it is quite 
natural for any person afflicted from it to be under a state 
of great mental stress and strain. 
Similar to the present study many workers have also 
reported an increased plasma histaminase activity in cancer 
patients (Baylin et al., 1970; 1972). While no change is 
observed in its activity in the cancer lung patients (Hansen 
et al., 1978). The level of Histaminase in plasma (Baylin et 
al., 1972) and in malignant effusion fluid is used as a 
cancer marker (Chiwei et aj.. , 1979). Our study a] so suggests 
the same, as the level of plasma histaminase increased 
gradually with the severity of the disease in cancer breast 
patients, i.e. from 1st stage to 3rd stage. Moreover, in the 
patients with metastases, the level of histaminase are found 
significantly enhanced than in patients with J ocalized 
cancers. It remained significantly onhatH-od even .iftor 
treatment in metastatic cancer patients and these patients 
did not show any improvement in their condition. Ttius, 
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Table-9: Circulating l e v e l s of RBC AchE, histaminase and 
MAO in various cancer pat i ents 
Cancer Stonach with 
. secondary in 
Oesophagus Stomach Colon Gall-bladder Liver Breast I II I I I Livtr 
mm I H I I 1 I J 1 1 J 
Plasma Histaminase f l [ f | f f ] \ ] f | | ]] 
PUs.a» i II i . t IJ 1 1 1 1 l i 
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histaminase activity can be used as a cancer marker as well 
as detecting any metastasis in the cancer patients or stages 
of breast cancer. 
Enhanced level of catecholamines are reported in cases 
of sarcoma and carcinoma (Udupa et al., 1980 and Patel et 
al., 1981). The decreased activity of MAO is observed in the 
patients of cancer oesophagus, stomach, colon, liver, breast 
and metastatic cancers, also suggest an enhance 
catecholamine levels in these cases. The enhance MAO 
activity as seen in the patients of cancer gall-bladder, 
suggest an overall increase in the metabolism of 
catecholamine in these cases. MAO is associated with 
alcoholism (Eric et al., 1993). The enhanced level of 
catecholamine produces tissue anoxia and hypoxia througli its 
known vasoconstrictive property. When this situation 
persists for a long time, in a susceptible organ the cell 
may transform into malignant cell, unmasking mutations 
brought about earlier in response to carcinogens, in effect 
acting as promoters and producing immunodepression. Several 
workers have reported a relationship between cancer and 
preceding stress (Milen, 1968; Baldwin, 1979; Moore, 1979; 
Selye, 1979 and Udupa et al., 1980). 
CONCWSIOli 
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The levels of circulating histaminase is increased in 
the patients of various cancer viz cancer of oesophagus, 
stomach, colon, gall-bladder, liver, breast and cancer 
stomach with secondary in liver. The increase in this 
parameter has a direct correlation with the severity of the 
disease. The activity of plasma monoamine oxidase is 
decrease in the patients of various cancer except cancer 
gall-bladder, suggest an overall increase in the metabolism 
of catecholamine in these cases. Thus the increased level of 
catecholamines through its known vasoconstrictive property 
causes anoxia in the tissue which helps in the 
transformation of normal cell into the malignant. 
The significantly raised level of histaminase and 
decreased activity of AChE showed a tendency to return 
towards normal value for these cancer patients who showed 
improvement (as in cancer breast). For the patients having 
severe cancer disease, as in the cases of metastatic cancer 
patients, however, these parameter did not exhibit any 
tendency to revert towards the normal value. It has been 
suggested that these parameter may be useful for the 
diagnostic purposes and for monitoring the progress (or lack 
thereof) of the patients. Since only 8 patients with 
metastates have been investigated, it is felt that further 
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work along these liver would be necessary to have a large 
statistical sample. These studies may lead to the 
development of a diagnostic tool to monitor the progress or 
to give an early information about metastasis. 
Cancer is an epidemic disease which is alarming both in 
a psychological sense and in its destructive effect on 
individuals. Studies are being carried out on every 
conceivable approach. Further experimental studies are 
required to confirm the present findings. 
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